Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?

References

• Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J. Natl Cancer Inst. 79(5), 1067–1075 (1987).
   PubMed Web of Science ®Google Scholar
• Brada M, Hoang-Xuan K, Rampling R et al. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 12(2), 259–266 (2001).
   PubMed Web of Science ®Google Scholar
• Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden and should be considered when allocating research funds. Br. J. Cancer 92(2), 241–245 (2005).
   PubMed Web of Science ®Google Scholar
• De Vleeschouwer S, Van Gool SW, Van Calenbergh F. Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells. Childs Nerv. Syst. 21(1), 7–18 (2005).
   PubMed Web of Science ®Google Scholar
• Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S. Dendritic cell therapy of high-grade gliomas. Brain Pathol. 19(4), 694–712 (2009).
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP et al.European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459–466 (2009).
   PubMed Web of Science ®Google Scholar
• Maes W, Van Gool SW. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol. Immunother. 60(2), 153–160 (2011).
   PubMed Web of Science ®Google Scholar
• De Vleeschouwer S, Arredouani M, Adé M et al. Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells. Cancer Immunol. Immunother. 54(4), 372–382 (2005).
   PubMed Web of Science ®Google Scholar
• De Vleeschouwer S, Fieuws S, Rutkowski S et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin. Cancer Res. 14(10), 3098–3104 (2008).
   PubMed Web of Science ®Google Scholar
• Ardon H, De Vleeschouwer S, Van Calenbergh F et al. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr. Blood Cancer 54(4), 519–525 (2010).
   PubMed Web of Science ®Google Scholar
• De Vleeschouwer S, Ardon H, Van Calenbergh F et al. Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination. Cancer Immunol. Immunother. doi:10.1007/s00262-012-1271-z (2012) (Epub ahead of print).
   Google Scholar
• Lake RA, Robinson BW. Immunotherapy and chemotherapy – a practical partnership. Nat. Rev. Cancer 5(5), 397–405 (2005).
   PubMed Web of Science ®Google Scholar
• Jameson SC. Maintaining the norm: T-cell homeostasis. Nat. Rev. Immunol. 2(8), 547–556 (2002).
   PubMed Web of Science ®Google Scholar
• Asavaroengchai W, Kotera Y, Mulé JJ. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl Acad. Sci. USA 99(2), 931–936 (2002).
   PubMed Web of Science ®Google Scholar
• Ge Y, Domschke C, Stoiber N et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol. Immunother. 61(3), 353–362 (2012).
   PubMed Web of Science ®Google Scholar
• Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 27(3), 247–254 (2001).
   PubMed Web of Science ®Google Scholar
• Newcomb EW, Demaria S, Lukyanov Y et al.The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin. Cancer Res. 12(15), 4730–4737 (2006).
   PubMed Web of Science ®Google Scholar
• Petrini B, Andersson B, Strannegard O, Wasserman J, Blomgren H, Glas U. Monocyte release and plasma levels of interleukin-6 in patients irradiated for cancer. In Vivo 6(5), 531–534 (1992).
   PubMedGoogle Scholar
• North RJ. Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol. Immunother. 16(3), 175–181 (1984).
   PubMed Web of Science ®Google Scholar
• Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res. 10(16), 5316–5326 (2004).
   PubMed Web of Science ®Google Scholar
• Ardon H, Van Gool SW, Verschuere T et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 Phase I/II trial. Cancer Immunol. Immunother. doi:10.1007/s00262-012-1261-1 (2012) (Epub ahead of print).
   Google Scholar